Case Report
Accepted on 26 Feb 2026
Ruxolitinib Reverses Systemic Vasculitis Driven by JAK2 V617F–Mutated Essential Thrombocythemia: a case report
in Inflammation
Frontiers in Immunology
17 articles related to "Essential Thrombocythemia Et"
Articles
Review
Published on 08 Sep 2023
BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
in Cancer Genetics and Oncogenomics
Frontiers in Genetics
doi 10.3389/fgene.2023.1241912
- 7,189 views
- 6 citations
Case Report
Accepted on 23 Jan 2026
Acute Mesenteric Vein Thrombosis and Small-Bowel Infarction Complicated by Essential Thrombocythemia: A case report
in Visceral Surgery
Frontiers in Surgery
- 132 views
Perspective
Published on 22 May 2017
Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2017.00103
- 6,948 views
- 2 citations
Original Research
Published on 21 Aug 2023
The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1224590
- 5,320 views
- 1 citation
Case Report
Published on 25 Aug 2025
Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report
in Thrombosis and Haemostasis
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2025.1658456
- 2,178 views
Original Research
Published on 19 Feb 2018
Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2018.00032
- 9,922 views
- 10 citations
Original Research
Published on 23 Nov 2022
A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.989984
- 4,595 views
- 4 citations
Case Report
Published on 08 May 2023
Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1176173
- 4,194 views
- 3 citations
Original Research
Published on 11 Aug 2023
The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1190305
- 4,186 views
- 1 citation
Original Research
Accepted on 09 Mar 2026
Dysregulation of the Immune Microenvironment in Essential Thrombocythemia: The Interplay of Core Genes and Inflammation-Related Signaling Pathways
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
Original Research
Published on 30 Apr 2020
Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia
in Inflammation
Frontiers in Immunology
doi 10.3389/fimmu.2020.00705
- 10,903 views
- 55 citations
Brief Research Report
Published on 04 Jan 2024
A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1265022
- 3,942 views
Review
Published on 01 Jun 2021
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
in Cytokines and Soluble Mediators in Immunity
Frontiers in Immunology
doi 10.3389/fimmu.2021.683401
- 23,407 views
- 98 citations
Original Research
Published on 12 Mar 2021
Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2021.637116
- 27,985 views
- 30 citations
Study Protocol
Published on 17 Apr 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial
in Hematology
Frontiers in Medicine
doi 10.3389/fmed.2025.1548590
- 5,969 views
- 2 citations